Abstract
BackgroundIn the FREEDOM pivotal phase 3 fracture trial, denosumab 60 mg every 6 months decreased the risk of new vertebral, nonvertebral and hip fractures at 3 years versus placebo.1 As...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have